معرفی
Stefan Krauss, a Professor and Director of the Centre of Excellence Hybrid Technology Hub at the University of Oslo's Institute of Medical Biology, specializes in developmental biology, organoid engineering, and biomedical technology. His research focuses on morphogenetic signaling in organoid development, organ-on-chip systems, and their applications in disease modeling. He leads the EU-funded SUMO project and collaborates with the Wellcome Leap consortium to develop micro-physiological systems for age-dependent stressor responses. With 130 peer-reviewed articles and six patents, his work spans prestigious journals like Cell and Nature. Key projects include FDA-validated LC-MS systems for organoid analysis and acoustic-based cell mechanotyping.
His research integrates advanced biotechnology with medical applications, emphasizing cross-disciplinary approaches to biomedical challenges. Krauss's contributions include pioneering organ-on-chip platforms modeling metabolic interactions between islets and liver tissue, as well as innovations in drug metabolism analysis using electromembrane extraction and preparative agarose gel electrophoresis. His lab also develops smart wireless multisensor platforms for optogenetic brain implants and 3D-printed microfluidic tools.
Notably, his discovery of the Shh signaling molecule was highlighted by Nature as a milestone in developmental biology. Current work explores glucose regulation in stem cell differentiation and anti-fibrotic effects of tankyrase inhibitors in preclinical models. The Hybrid Technology Hub under his direction bridges engineering and medicine, advancing organoid-based technologies for precision healthcare.
